rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Vemurafenib as first-line therapy in <i>BRAF</i>-V600E-mutant Erdheim-Chester disease with CNS involvement.
|
31748352 |
2019 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E mutations are not an oncogenic driver of solitary xanthogranuloma and reticulohistiocytoma: Testing may be useful in screening for Erdheim-Chester disease.
|
31639332 |
2019 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E mutations are not an oncogenic driver of solitary xanthogranuloma and reticulohistiocytoma: Testing may be useful in screening for Erdheim-Chester disease.
|
31639332 |
2019 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Vemurafenib as first-line therapy in <i>BRAF</i>-V600E-mutant Erdheim-Chester disease with CNS involvement.
|
31748352 |
2019 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Significant differences were the eyelid involvement in XG, orbital nerve involvement, and an elevated IgG4+/IgG+ ratio in IgG4-RD and the only genetic abnormality found was BRAF V600E mutation in the Erdheim-Chester disease subgroup of XG.
|
26882062 |
2017 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Significant differences were the eyelid involvement in XG, orbital nerve involvement, and an elevated IgG4+/IgG+ ratio in IgG4-RD and the only genetic abnormality found was BRAF V600E mutation in the Erdheim-Chester disease subgroup of XG.
|
26882062 |
2017 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults.
|
26858028 |
2016 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We collected CSF from patients with BRAF V600E or K-mutated melanoma (N=8) or BRAF V600E mutated Erdheim-Chester Disease (ECD) (N=3) with suspected central nervous system (CNS) involvement on the basis of neurological symptoms (10/11), MRI imaging (8/11), or both.
|
27863426 |
2016 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A BRAF(V600E) mutation in a non-LCH histiocytic lesion with a xanthogranuloma phenotype (CD163/CD68/CD14/fascin/Factor 13a) should prompt an Erdheim-Chester disease workup.
|
26454140 |
2016 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We collected CSF from patients with BRAF V600E or K-mutated melanoma (N=8) or BRAF V600E mutated Erdheim-Chester Disease (ECD) (N=3) with suspected central nervous system (CNS) involvement on the basis of neurological symptoms (10/11), MRI imaging (8/11), or both.
|
27863426 |
2016 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults.
|
26858028 |
2016 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A BRAF(V600E) mutation in a non-LCH histiocytic lesion with a xanthogranuloma phenotype (CD163/CD68/CD14/fascin/Factor 13a) should prompt an Erdheim-Chester disease workup.
|
26454140 |
2016 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Erdheim-Chester disease (ECD) is a rare form of non-Langerhans-cell histiocytosis, associated in more than 50% of cases to BRAF(V600E) mutations in early multipotent myelomonocytic precursors or in tissue-resident histiocytes.
|
25744785 |
2015 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Patients with Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD) have a high frequency of BRAF(V600E) mutations and respond to RAF inhibitors.
|
25324352 |
2015 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Does the BRAF(V600E) mutation herald a new treatment era for Erdheim-Chester disease? A case-based review of a rare and difficult to diagnose disorder.
|
25735579 |
2015 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.
|
25422482 |
2015 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Patients with Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD) have a high frequency of BRAF(V600E) mutations and respond to RAF inhibitors.
|
25324352 |
2015 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Erdheim-Chester disease (ECD) is a rare form of non-Langerhans-cell histiocytosis, associated in more than 50% of cases to BRAF(V600E) mutations in early multipotent myelomonocytic precursors or in tissue-resident histiocytes.
|
25744785 |
2015 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Does the BRAF(V600E) mutation herald a new treatment era for Erdheim-Chester disease? A case-based review of a rare and difficult to diagnose disorder.
|
25735579 |
2015 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.
|
25422482 |
2015 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Erdheim-Chester disease with an 18F-fluorodeoxyglucose-avid breast mass and BRAF V600E mutation.
|
24531980 |
2014 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease.
|
25003820 |
2014 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Erdheim-Chester disease with an 18F-fluorodeoxyglucose-avid breast mass and BRAF V600E mutation.
|
24531980 |
2014 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease.
|
25003820 |
2014 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses.
|
22879539 |
2012 |